Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

This ‘Strong Buy’ Stock Has More Than Tripled Today. Should You Buy It Here?

Praxis Precision Medicines (PRAX) shares nearly tripled on Thursday after the biotechnology firm reported promising late-stage results for its experimental drug ulixacaltamide. 

According to the company’s press release, ulixacaltamide significantly improved daily functioning in patients with essential tremor across two Phase 3 trials. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.